Abstract:Abstract Abstract 4524 Graft failure or graft rejection is a serious and potentially life-threatening complication after allogeneic hematopoietic stem cell transplantation (HSCT), which occurs at an overall frequency of less than 5%. Before 2005, in our unit we tried to manage this complication by infusion of hematopoietic stem cells (HSCs) from an alternative donor (n=2) or cord blood (n=2). Unfortunately, these 4 patients could not achieve neutrophil engraftment and died of serious infections. Thus, in case of engrafment failure, donor reneging or other unpredictable conditions, we have advised the storage of “back-up” cells for all patients undergoing unrelated allo-HSCT since 2005. Before allo-HSCT, patients with chronic myelogenous leukemia (CML) mobilized with G-CSF after intravenous cyclophosphamide 2g/m2 for 2 days, whereas patients with other acute leukemia mobilized with G-CSF during the agranulocytosis phase after chemotherapy. “Back-up” cells were harvested as soon as white blood cell count was greater than 2×109/L, and cryopreserved in liquid nitrogen. From Jan 2005 to Dec 2009, 118 patients stored autologous “backup” cells, among whom 19 CML patients underwent fludarabine based reduced intensity conditioning regimen, and other patients underwent BuCy based myeloablative conditioning regimen. All patients underwent non-manipulated marrow or peripheral stem cell transplantation. None of these 118 patients developed harvest- related- complication when “back-up” cell mobilization and harvest. The medial mononuclear cells (MNC) count in “back-up” cells was 5×108/kg (2.71-11.3×108/kg). Engraftment was defined as absolute neutrophil count >0.5×109/L for 3 successive days and platelet count >20×109/L independent of transfusions. Engraftment was monitored by following complete blood counts, chimerism studies and BM biopsies. In total, 4 patients (2 of 19 patients who underwent reduced intensity conditioning regimen and 2 of 99 patients who underwent myeloablative conditioning regimen) re-infused “back-up” cells at once when the engraft failure was diagnosed. The media interval between allo-HSCT and re-infusion of “Back-up” cells were 39.5 day (range from 24 days to 50 days). The median MNC counts of re-infused cells were 4.49×108/Kg (range from 4.10 to 5.15). 3 of the 4 patients achieved successful hematological reconstitution within 13 days, and the fourth patient was still pancytopenia during 23 days after the re-infusion of “back-up” cells with BM examination revealing severe BM hypoplasia. However, second HSCT from a haploidentical donor following a fludarabine (Flu)- and anti-thymocyte globulin (ATG)-based conditioning regimen resulted in hematological reconstitution. After re-infusion of “Back-up” cells, 2 patients with CML and 1 patient with Ph+ ALL received continuing imatinib treatment and the fourth patient who underwent second haploidentical donor HSCT was watchful waited. One patient who diagnosed with CML was still alive for 4.5 years after the re-infusion of “back-up” cells, and recurrent detection of the expression of BCR/ABL fusion gene showed complete cytogenetic remission. Another CML patient died of progression of disease and intracranial hemorrhages in 7 months after the re-infusion of “back-up” cells The patient who diagnosed with ALL (Ph+) was still alive for 2.3 years after the re-infusion of “back-up” cells, and recurrent bone marrow aspiration examinations showed complete remission. The patient diagnosed with AML and underwent second haploidentical transplantation was alive in CR for 1.8 years. Our experience suggests that re-infusion of cryopreserved “back-up” cells could provide a safe and effective therapeutic strategy for engraftment failure after unrelated allo-HSCT in adult patients. Disclosures: No relevant conflicts of interest to declare.

Transporting bone marrow for in vitro purging before autologous reinfusion

A Retrospective Study of Autologous Stem Cell Mobilization by G-CSF in Combination with Chemotherapy in Patients with Multiple Myeloma and Lymphoma.

“Back-Up” Stem Cell Harvest is Beneficial for Patients Receiving Unrelated Donor Allogeneic Hematopoietic Cell Transplantation.

Cryopreservation of Human Bone-Marrow after Purging T-Cells or Tumor-Cells

Peripheral blood mononuclear cells cryopreservation and transportation

How to decrease bone marrow collection volume and risk contaminations via the operating room cell concentration?

Isolation and Cryopreservation of Mononuclear Cells from Peripheral Blood and Bone Marrow of Blood Cancer Patients

Chemotherapy Combined With Granulocyte Colony Stimulating Factor (G-Csf) For Mobilization Of Cd34(+) Cells In Lymphoma And Multiple Myeloma Patients

[Mobilization of Autologous Peripheral Blood Stem Cells by Chemotherapy and Recombinant Granulocyte Colony-Stimulating Factor (G-CSF) and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)].

The HSCT procedure (I): Mobilization, collection, manipulation, and cryopreservation of a HSC graft

Non-cryopreserved autologous peripheral blood stem cell transplantation for multiple myeloma and lymphoma in countries with limited resources: practice considerations from the Worldwide Network for Blood and Marrow Transplantation

Description of a closed plastic bag system for the collection and cryopreservation of leukapheresis-derived blood mononuclear leukocytes and CFUc from human donors

Autologous transplantation in acute myeloid leukemia: peripheral blood stem cell harvest after mobilization in steady state by granulocyte colony-stimulating factor alone

Stem cell collection in unmanipulated HLA-haploidentical/mismatched related transplantation with combined granulocyte-colony stimulating factor-mobilised blood and bone marrow for patients with haematologic malignancies: the impact of donor characteristics and procedural settings

Optimal Storage Conditions for Apheresis Research (OSCAR): a Biomedical Excellence for Safer Transfusion (BEST) Collaborative study

Expanding the reach of commercial cell therapies requires changes at medical centers

Biological characterization of CD34+ cells mobilized into peripheral blood

The mobilization assessment of autologous peripheral blood stem cells by vinorelbine and G-CSF on solid tumor patients

Use of concurrent G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells in children with malignant disease

Collection, tumor contamination, and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma

A Comparative Study of B Cell Blast Isolation Methods from Bone Marrow Aspirates of Pediatric Leukemia Patients